Catalyst

REGN earnings

Apr 29, 2026

REGN earnings — 2026-04-29

Reported the quarter ending 2026-03-31: revenue $3.61B, diluted EPS $6.75, net income $727M (SEC filing). Across the print the stock moved -3.4% (close before → first close after).

Backfilled from filed financials — a record of the print, not an analyst read.

10 events

DateTypeEvent

Apr 28 ScanBiotech Scan Apr 26 UpdateBiotech Candidates Apr 26 ScanBiotech Scan Apr 13 Scan1 — BIOTECH SCAN Apr 10 UpdateBiotech Candidates Apr 10 ScanBiotech Scan May 23 ArticleDaily Actions — May 23, 2026 (R30-A Phase 4) Apr 3 ScanBiotech Scan Mar 31 ScanBiotech Scan May 29 UpdateBiotech Candidates

No direct external sources are attached to this read.